Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation

Gastroenterology

Volumn 122, Issue 2, 2002, Pages 264-273

  Bock, C Thomas ^a   Tillmann, Hans L ^a   Torresi, Joseph ^c   Klempnauer, Jürgen ^a   Locarnini, Stephen ^b   Manns, Michael P ^a   Trautwein, Christian ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ASPARTIC ACID; BILIRUBIN; DNA POLYMERASE; FAMCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MESSENGER RNA; METHIONINE; NUCLEOSIDE; TYROSINE; VIRUS DNA;

ARTICLE; CASE REPORT; CONTROLLED STUDY; DISEASE COURSE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MUTANT; MUTATION; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTHROMBIN TIME; SITE DIRECTED MUTAGENESIS; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION;

EID: 0036161381     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.31015     Document Type: Article

References (53)

1. The treatment of chronic viral hepatitis
2. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B
3. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection
4. Placebo-controlled trial of recombinant alpha 2-interferon in Chinese HBsAg-carrier children
5. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
6. Prostaglandin E plus famciclovir-a new concept for the treatment of severe hepatitis B after liver transplantation
7. A preliminary trial of lamivudine for chronic hepatitis B infection
8. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis
9. Lamivudine as initial treatment for chronic hepatitis B in the United States
10. A one-year trial of lamivudine for chronic hepatitis B. Asia hepatitis lamivudine study group
11. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
12. Significance of mutations in the HBV polymerase selected by nucleoside analogues and implications for controlling disease
13. Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation
14. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
15. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation
16. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient
17. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: Hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss
18. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis
19. Liver transplantation in HBs antigen (HBsAg) carriers 1991. Prevention of hepatitis B virus (HBV) recurrence by passive immunization
20. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis
21. The enhancer I core region contributes to the replication level of hepatitis B virus In vivo and in vitro
22. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus
23. A pre-S mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly
24. The pre-S region determines the intracellular localization and appearance of hepatitis B virus
25. The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen
26. Hepatitis B virus core gene mutations which block nucleocapsid envelopment
27. Molecular virology and pathogenesis of hepatitis B
28. Genetic variation in hepatitis B virus
29. Vaccine-induced escape mutant of hepatitis B virus
30. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
31. Hepatitis B virus unable to secrete e antigen
32. A domain of the hepadnavirus capsid protein is specifically required for DNA maturation and virus assembly
33. Subtype-independent immature secretion and subtype-dependent replication deficiency of a highly frequent, naturally occurring mutation of human hepatitis B virus core antigen
34. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
35. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance
36. Locations of anti-AIDS drugs binding sites and resistance mutations in the three dimensional structure of HIV-1 reverse transcriptase
37. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to didieoxynucleotides depends on the template length
38. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation
39. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1
40. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase
41. Multiple resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain
42. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV
43. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the non-nucleoside reverse transcriptase inhibitor loviride
44. HIV-1 isolates that exhibit dose-dependent NNRTI stimulation of reverse transcripatase activity and viral replication
45. A novel HIV-1 RT mutation (M230L) confers NNRTI resistance and dose-dependent stimulation of replication
46. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance
47. Clearance of the original hepatitis B virus YMDD-motif mutants with the emergence of distinct lamvudine-resistant mutants during prolonged lamivudine therapy
48. Liver transplantation in European patients with the hepatitis B surface antigen
49. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation
50. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis
51. Predictions of the emergence of vaccine-resistant hepatitis B virus in The Gambia using a mathematical model
52. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan
53. Current status of HBV vaccine escape variants-a mathematical model of their epidemiology